Linden Thomas Advisory Services LLC Sells 375 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Linden Thomas Advisory Services LLC reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,184 shares of the biotechnology company’s stock after selling 375 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Sarepta Therapeutics were worth $1,360,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Sarepta Therapeutics by 105.9% during the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $59,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 2.2 %

Sarepta Therapeutics stock opened at $116.46 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a fifty day moving average of $122.17 and a 200 day moving average of $128.31. The stock has a market cap of $11.12 billion, a PE ratio of 93.17 and a beta of 0.77. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25.

Insiders Place Their Bets

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SRPT. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. HC Wainwright reissued a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, January 15th. Evercore ISI dropped their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.